MOMO'S BREAKOUT BOARD

[StockDetective]

$ARYC blue sky’s!

Due Diligence link:

https://cdn.discordapp.com/attachments/357369664193560596/459932549062590475/Arrayit_Due_Diligence_Report_.pdf


ARYC chart:
http://stockcharts.com/h-sc/ui?s=Aryc

100% BUY recommendation by Barchart:
https://www.barchart.com/stocks/quotes/ARYC/opinion


Recent Press Release:

Arrayit Corporation Reports Clinical Instrumentation Sale to the United States Food and Drug Administration
Arrayit Corporation Completes Allergy Testing Pilot Program for One of the Nation’s Largest Retail Chains
Arrayit Corporation Announces Nationwide Allergy Testing Sales and Distribution Network
Arrayit Corporation Reports Clinical Instrumentation Sale to the United States Food and Drug Administration

Sunnyvale, July 16, 2018 (GLOBE NEWSWIRE) -- July 16, 2018 - Sunnyvale, CA - Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces the sale of clinical instrumentation to the United States Food and Drug Administration (FDA). Arrayit uses the same clinical instrumentation in its Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the Centers for Medicare and Medicaid Services (CMS) and the State of California Department of Public Health (CDPH). The instrumentation reads and reports test results for the company's allergy and dietary wellness tests and pipeline tests for ovarian cancer and Parkinson's Disease (PD).

Arrayit recently scored 100% on immunoglobulin E (IgE) proficiency testing with the College of American Pathologists, announced a nationwide sales network of 1,700 professional sales representatives to sell and distribute the company's finger stick tests, and completed pilot testing with one the nation's largest chains of retail stores. Arrayit microarray tests conveniently use a few drops of blood collected on a blood card to assist doctors in identifying and treating allergy, asthma, dietary intolerance and pipeline indications for ovarian cancer and PD. The company recently met with top officials at the FDA to discuss FDA approval of a major product line. The FDA ensures the safety of food, drugs and medical devices by regulating consumer products exceeding $1,000,000,000,000 ($1 trillion) in annual revenues.

Arrayit CEO Rene Schena states, "The sale of clinical instrumentation to the FDA advances our personalized medicine initiatives by strengthening ties with the nation's preeminent regulatory agency. Our transformative healthcare products and services benefit from transparency in the hands of top FDA scientists."

https://www.nasdaq.com/press-release/arrayit-corporation-reports-clinical-instrumentation-sale-to-the-united-states-food-and-drug-20180716-00167


Recent company Tweets:

Arrayit signs capital financing agreement with a top buy-side analyst at a leading corporate intelligence firm headquartered in London UK with offices in New York and providing buy-side intelligence to high net worth retail investors, institutional investors and hedge funds.

Arrayit provides 7/2/18 FDA update: (1) excellent meeting, (2) large attendance by FDA top brass, (3) insightful and instructive, (4) our entire clinical team wishes to thank the agency for their feedback and generosity, and (5) we believe that our test will receive FDA approval.

Arrayit senior management receives NASDAQ and NYSE up-listing proposal from small and mid-cap consulting experts http://uplisting.com focusing on growth companies seeking to improve and enhance shareholder value by listing on a major stock exchange http://www.uplisting.com

Arrayit senior management receives Industry Innovators television interview invitation hosted by elite business and affluent consumer leaders Talk Business 360 airing July 28 2018 on Fox Business Network and available to 80+ million viewers nationwide (link: http://talkbusiness360.com) talkbusiness360.com

Arrayit senior management receives Industry Innovators television interview invitation hosted by elite business and affluent consumer leaders Talk Business 360 airing July 28 2018 on Fox Business Network and available to 80+ million viewers nationwide https://t.co/VL77SGOdO9 pic.twitter.com/fy4efcEvFV

— Arrayit Corporation (@arrayit) July 10, 2018

Arrayit Corporation (ARYC) CEO Rene Schena will provide a letter to shareholders as soon as the company resumes current financial reporting (summer of 2018).

http://arrayit.com/Microarray_Investor/Arrayit_Letter_to_Shareholders/arrayit_letter_to_shareholders_from_the_ceo.html


Arrayit Corporation (ARYC) complies with federal rules and regulations governing public companies, including making disclosures with the United States Securities and Exchange Commission (SEC). We will resume quarterly and annual financial filings during the summer of 2018. Please consult ARYC data at sec.gov for our current and past filings.

http://arrayit.com/Microarray_Investor/ARYC_SEC_Filings/aryc_sec_filings.html